<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Sept. 2, 2020 (HealthDay News) — There is no association between treatment type for hyperthyroidism and later risk of solid cancer mortality, according to a study published online July 23 in JAMA Network Open<\/i>.<\/p>\n
Cari M. Kitahara, Ph.D., from the National Cancer Institute in Bethesda, Maryland, and colleagues examined data from 31,363 patients treated at multiple centers for hyperthyroidism (1946 through 1964). Follow-up continued through December 2014 (mean, 26.0 years). Solid cancer mortality rates in each treatment group (radioactive iodine [RAI], antithyroid drugs [ATDs], surgery, or a combination of these treatments) were compared with expected rates from the general population.<\/p>\n
The researchers found that after excluding prior cancers, solid cancer standardized mortality ratios (SMRs) were not elevated in any of the treatment groups (SMRs: 0.82 for surgery only [95 percent confidence interval (CI), 0.66 to 1.00], 0.90 for drugs only [95 percent CI, 0.74 to 1.09], 0.88 for drugs and surgery [95 percent CI, 0.84 to 0.94], 0.90 for RAI only [95 percent CI, 0.84 to 0.96], 0.66 for surgery and RAI [95 percent CI, 0.52 to 0.85], 0.94 for drugs and RAI [95 percent CI, 0.89 to 1.00], and 0.85 for drugs, surgery, and RAI [95 percent CI, 0.75 to 0.96]). There were no significantly elevated risks seen for solid cancer death in any treatment group. There was a significant increase noted in risk for solid cancer mortality across levels of total administered activity among RAI-treated patients (hazard ratio, 1.08 per 370 MBq; 95 percent CI, 1.03 to 1.13); among patients treated with only RAI, this association was stronger (hazard ratio, 1.19 per 370 MBq; 95 percent CI, 1.09 to 1.30).<\/p>\n
“The findings suggest that the association between radioactive iodine treatment and solid cancer mortality is dose dependent,” the authors write.<\/p>\n
One author disclosed receiving institutional research funding from Exelixis and Eli Lilly.<\/p>\n